Neoadjuvant immunotherapy for resectable esophageal cancer: A review

Esophageal cancer (EC) is one of the most common cancers worldwide, especially in China. Despite therapeutic advances, the 5-year survival rate of EC is still dismal. For patients with resectable disease, neoadjuvant chemoradiotherapy (nCRT) in combination with esophagectomy is the mainstay of treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qing, Liu, Ting, Ding, Zhenyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773255/
https://www.ncbi.nlm.nih.gov/pubmed/36569908
http://dx.doi.org/10.3389/fimmu.2022.1051841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773255/
https://www.ncbi.nlm.nih.gov/pubmed/36569908
http://dx.doi.org/10.3389/fimmu.2022.1051841

Ejemplares similares